HC Wainwright Increases Earnings Estimates for MacroGenics

MacroGenics, Inc. (NASDAQ:MGNX) – Analysts at HC Wainwright raised their Q1 2025 earnings estimates for MacroGenics in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst R. Burns now expects that the biopharmaceutical company will earn ($0.69) per share for the quarter, up from their prior estimate of ($0.70). HC Wainwright currently has a “Neutral” rating and a $2.00 target price on the stock. The consensus estimate for MacroGenics’ current full-year earnings is ($1.06) per share. HC Wainwright also issued estimates for MacroGenics’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.89) EPS.

Separately, StockNews.com cut shares of MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, March 21st. Nine investment analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, MacroGenics has an average rating of “Hold” and a consensus target price of $7.38.

MacroGenics Price Performance

MacroGenics stock opened at $1.48 on Thursday. The business has a 50 day simple moving average of $2.54 and a 200-day simple moving average of $3.17. MacroGenics has a 12 month low of $1.46 and a 12 month high of $19.54. The stock has a market capitalization of $93.37 million, a PE ratio of -0.94 and a beta of 2.12.

MacroGenics (NASDAQ:MGNX) last posted its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). MacroGenics had a negative return on equity of 89.42% and a negative net margin of 69.07%. The company had revenue of $49.40 million for the quarter, compared to analyst estimates of $34.17 million.

Institutional Investors Weigh In On MacroGenics

Several institutional investors have recently made changes to their positions in MGNX. Wasatch Advisors LP increased its holdings in shares of MacroGenics by 37.6% in the 4th quarter. Wasatch Advisors LP now owns 3,488,493 shares of the biopharmaceutical company’s stock valued at $11,338,000 after purchasing an additional 952,691 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in MacroGenics in the fourth quarter valued at about $2,787,000. JPMorgan Chase & Co. lifted its position in shares of MacroGenics by 68.3% during the 4th quarter. JPMorgan Chase & Co. now owns 546,807 shares of the biopharmaceutical company’s stock valued at $1,777,000 after acquiring an additional 221,905 shares during the period. Renaissance Technologies LLC boosted its stake in shares of MacroGenics by 69.1% during the 4th quarter. Renaissance Technologies LLC now owns 538,523 shares of the biopharmaceutical company’s stock worth $1,750,000 after acquiring an additional 220,100 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. grew its holdings in shares of MacroGenics by 5.5% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,175,665 shares of the biopharmaceutical company’s stock worth $10,321,000 after acquiring an additional 164,938 shares during the period. 96.89% of the stock is currently owned by hedge funds and other institutional investors.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.